14 February 2019
Canada-based AbCellera has announced it has signed a multi-year, multi-target agreement with Novartis under which its antibody discovery technology will be leveraged by the Swiss pharma giant for up to...
12 February 2019
Merck has announced the US Food and Drug Administration (FDA) has granted priority review for its supplementary biologics license application (sBLA) for Keytruda as first line treatment for patients with...
8 February 2019
Researchers from the Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust have announced promising results from a phase I/II into tisotumab vedotin (TV) in patients with...
5 February 2019
French pharma giant Sanofi has unveiled that its multiple myeloma drug isatuximab has met its primary endpoint of prolonged progression-free survival in a Phase III trial.
4 February 2019
French gene therapy company GenSight has announced its GS010 drug indicated for eye condition Leber Hereditary Optic Neuropathy (LHON) failed to meet the primary endpoint at week 48 of a...
31 January 2019
A US Independent Data Monitoring Committee has recommended that patients in the placebo group of Johnson & Johnson subsidiary Janssen’s Phase III TITAN trial of Erleada (apalutamide) plus androgen deprivation...
30 January 2019
Danish drug maker Orphazyme has announced positive results from its Phase II/III trial of arimoclomol in rare genetic disease Niemann-Pick disease type C (NPC).
25 January 2019
The US Food and Drug Administration (FDA) has stated that Eli Lilly’s Lartruvo (olaratumab) therapy should not be initiated for soft tissue sarcoma patients and patients already taking the drug...
18 January 2019
Chinese Sino Pharmaceutical has announced that China’s National Medical Products Administration has approved its subsidiary Chia-Tai Tianqing Pharmaceutical’s anti-tumour drug lenalidomide for multiple melanoma.
11 January 2019
Japan-based Sumitomo Dainippon Pharma has published positive results from the phase III JEWEL trial into its drug Latuda (lurasidone hydrochloride) for patients with schizophrenia.